Repare Therapeutics Inc. is a clinical-stage precision oncology company that uses a synthetic lethality approach to develop novel cancer therapeutics. Its SNIPRx platform, enabled by CRISPR, helps discover targeted therapies focused on genomic instability and DNA damage repair. The pipeline includes lunresertib (RP-6306), a PKMYT1 inhibitor in Phase 1/2 trials; camonsertib (RP-3500), an ATR inhibitor in Phase 1/2 trials; RP-1664, a Phase 1 PLK4 inhibitor; RP-3467, a preclinical polymerase theta ATPase inhibitor; and other undisclosed preclinical programs. RP-3500 is an oral ATR inhibitor for treating solid tumors with DNA damage repair-related genomic alterations. The RPTX average annual return since 2020 is shown above.
The Average Annual Return on the RPTX average annual return since 2020 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether RPTX average annual return since 2020 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the RPTX average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|